Fakultni Thomayerova nemocnice

The Department of Pneumology at Fakultni Thomayerova nemocnice focuses on clinical trials for respiratory tract diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and chronic obstructive pulmonary disease. The primary goal is to evaluate new therapies, improve disease monitoring, and ensure long‑term safety.

• Idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung disease
• Pulmonary sarcoidosis with or without extrapulmonary involvement
• Chronic obstructive pulmonary disease treatment optimization

Trials enroll adults with moderate to severe disease and often compare innovative agents to standard of care or placebo, with endpoints that include lung‑function preservation and reduction of corticosteroid use.

A broad oncology program at the site investigates cancer across multiple organ systems, including renal cell carcinoma, lung cancer, bladder cancer, and breast cancer. Studies aim to test combination immunotherapies, targeted agents, and adjuvant treatments to improve survival and disease‑free outcomes.

• Advanced clear cell and non‑clear cell renal cell carcinoma
• Non‑small cell and small cell lung cancer, including resectable and metastatic stages
• High‑risk non‑muscle‑invasive bladder cancer and urothelial carcinoma
• Hormone‑receptor positive, HER2‑negative and triple‑negative breast cancer

Participants range from newly diagnosed patients to those with refractory disease, and trials frequently assess progression‑free survival, overall survival, and quality‑of‑life measures.

The research team conducts trials targeting immune‑mediated disorders such as sarcoidosis, psoriatic arthritis, and multiple sclerosis. Objectives include reducing reliance on steroids, evaluating novel biologics, and measuring disease activity through imaging and biomarkers.

• Pulmonary sarcoidosis with extrapulmonary manifestations
• Psoriatic arthritis and related spondyloarthropathies
• Relapsing multiple sclerosis (RMS) and secondary progressive MS

Studies often compare new monoclonal antibodies or small‑molecule inhibitors against existing standards, with endpoints such as ACR50 response, MRI lesion activity, and corticosteroid‑sparing effects.

Clinical research at the hospital addresses cardiovascular risk and heart failure, evaluating lipid‑lowering therapies, antithrombotic agents, and interventions to prevent major adverse cardiac events.

• High‑risk patients without prior myocardial infarction or stroke
• Heart failure with reduced ejection fraction
• Hypertension and hypertriglyceridemia management

Trials typically measure outcomes such as cardiovascular death, myocardial infarction, ischemic stroke, and hospitalization rates, while monitoring safety profiles.

The site’s metabolic program investigates conditions linked to obesity, type 2 diabetes, and dyslipidemia, focusing on therapies that modify weight, glycemic control, and triglyceride levels.

• Obesity and related cardiovascular outcomes
• Type 2 diabetes with emphasis on glucose‑lowering agents
• Severe hypertriglyceridemia and associated pancreatitis risk

Endpoints include changes in body‑mass index, HbA1c, lipid profiles, and incidence of cardiovascular events, providing a comprehensive view of metabolic health.

Innovative diagnostic tools and imaging agents are evaluated at Fakultni Thomayerova nemocnice, including MRI contrast agents and breath‑biopsy technology for early lung cancer detection.

• Gadoquatrane versus macrocyclic gadolinium‑based contrast agents
• OWL‑EVO1 breath biopsy test for differentiating lung cancer from benign conditions
• Inhaled corticosteroid/bronchodilator combination safety assessment (CHF5993 pMDI)

These studies aim to improve diagnostic accuracy, reduce adverse events, and enhance patient safety across a range of pulmonary and oncologic applications.